148 related articles for article (PubMed ID: 27438692)
1. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
[TBL] [Abstract][Full Text] [Related]
2. Intestinal Perforation in a Patient with Colon Cancer during Treatment with Regorafenib: A Case Report and Review of the Literature.
Ouchi R; Okada K; Usui K; Kurata N; Suzuki S; Nagao M; Watanabe Y; Koyama K
Tohoku J Exp Med; 2021 Jul; 254(3):207-211. PubMed ID: 34321384
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib use as a possible cause of intestinal perforation.
Adenis A; Kotecki N; Decanter G; Clisant S; Penel N
Acta Oncol; 2013 Nov; 52(8):1789-90. PubMed ID: 24024697
[No Abstract] [Full Text] [Related]
4. Intestinal perforation after regorafenib usage.
Sarıcı B; Karakaş S; Uylas U; Aktaş A; Dikilitaş M; Kayaalp C
Turk J Gastroenterol; 2018 Mar; 29(2):245-247. PubMed ID: 29749339
[No Abstract] [Full Text] [Related]
5. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
6. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
Kikuchi K; Ogawa M; Sasaki A
J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
[TBL] [Abstract][Full Text] [Related]
7. [Two Episodes of Colostomy-Associated Intestinal Perforation during Chemotherapy for Metastatic Rectal Cancer].
Tamura H; Otani A; Tsukui M; Toge K; Otani T; Hirose Y; Morimoto Y; Yoshino K; Kido T; Endo K; Kameyama H; Kobayashi T; Wakai T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2172-2174. PubMed ID: 28133259
[TBL] [Abstract][Full Text] [Related]
8. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
9. [Two Cases of Bowel Perforation during Chemotherapy with Bevacizumab to Metastatic Rectal Cancer].
Miyake Y; Ikeda K; Murakami M; Oka Y; Nezu R; Kurokawa E; Kikkawa N
Gan To Kagaku Ryoho; 2015 Dec; 42 Suppl 1():75-8. PubMed ID: 26809419
[TBL] [Abstract][Full Text] [Related]
10. [A case of diffuse infiltrating carcinoma of large intestine with liver metastases effectively treated with systemic chemotherapy].
Murahashi K; Takagaki K; Kishimoto K; Mino A; Nishino K; Aoki T; Sowa M
Gan To Kagaku Ryoho; 2011 Apr; 38(4):673-6. PubMed ID: 21499003
[TBL] [Abstract][Full Text] [Related]
11. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
[TBL] [Abstract][Full Text] [Related]
12. [A Patient with Cavitated Pulmonary Metastases Treated with Regorafenib].
Taniguchi M; Mori M; Sata N; Fujii H
Gan To Kagaku Ryoho; 2016 Jun; 43(6):757-9. PubMed ID: 27306815
[TBL] [Abstract][Full Text] [Related]
13. Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report.
Akamine T; Ando K; Oki E; Saeki H; Nakashima Y; Imamura YU; Ohgaki K; Maehara Y
Anticancer Res; 2015 Jul; 35(7):4037-41. PubMed ID: 26124352
[TBL] [Abstract][Full Text] [Related]
14. Single dose regorafenib-induced hypertensive crisis.
Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
[TBL] [Abstract][Full Text] [Related]
15. [Long-Term Survival of a Patient with Metastatic Liver and Para-Aortic Lymph Node Cancer from Colon Cancer Treated with Regorafenib].
Watanabe N; Akagi S; Inoue H; Nakatsuji H; Ito H; Toma A; Nakamura K; Ochiai T; Otsuji E
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1732-1734. PubMed ID: 29394758
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
17. Bilateral sensorineural hearing loss induced by regorafenib.
Cheng J; Wang L; Zhu LN; Wang L
J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
Yoshii Y; Furukawa T; Aoyama H; Adachi N; Zhang MR; Wakizaka H; Fujibayashi Y; Saga T
Int J Oncol; 2016 Apr; 48(4):1477-84. PubMed ID: 26820693
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
20. [A case of metachronous gastrointestinal perforation of a patient with metastatic rectal cancer during treatment with bevacizumab-based chemotherapy].
Sadatomo A; Koinuma K; Miki A; Horie H; Yasuda Y
Gan To Kagaku Ryoho; 2013 Jul; 40(7):943-5. PubMed ID: 23863742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
